Huadong Medicine has obtained approvals for three new products at the start of the year, which is nearly half of last year's total.|Quick read announcement.

1. Huadong Medicine announced today that three products have received approval for market entry, while a total of seven products were approved last year; 2. Among them, a hyaluronic acid product for medical aesthetics and a chemical drug for the treatment of ovarian cancer received domestic approval, while a medical instrument for assessing kidney function received approval in the USA; 3. Huadong Medicine believes that the approvals will not have a significant impact on the company's current financial situation and operational results.

cls.cnJan 20 10:31 ET

Opening more new stores but struggling to make a profit, Yixintang Pharmaceutical's net income is expected to drop by over 70% last year | Interpretations

① Yixintang Pharmaceutical expects a Net income decline of 72.7%–81.8% in 2024 compared to the same period last year; ② The company stated that the performance variation is mainly due to the expansion of the company's stores leading to increased Operation costs, as well as some new and relatively new stores being in the initial loss stage.

cls.cnJan 17 09:47 ET

The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 08:42 ET

The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.

According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.

cls.cnDec 25, 2024 19:09 ET

Not recognized by the capital markets? Guangxi Liuyao Group: The company's stock price does not match its value | Direct coverage of the earnings conference.

1. At the earnings conference, the chairman of guangxi liuyao group, Zhu Chaoyang, stated that the company's market cap, stock price, and company value are not aligned; 2. The company secretary Xu Yang stated that the company will improve the issue of high accounts receivable through measures such as strengthening the assessment of collection indicators for business personnel; 3. Xu Yang introduced the progress of the company's AI application business in response to investors' concerns.

cls.cnDec 9, 2024 07:31 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27, 2024 09:29 ET